- A subsequent health economic analysis of previously published data from a 1-arm, multicenter study in the United States, with no control group.
- The exposure was use of an AI-powered digital self-management tool for chronic pain, and costs and QALYs were modeled from baseline to 6 and 12 weeks.
- At 12 weeks, the authors estimated $127 per user in reduced health care costs, $930 per user in increased annual productivity, and 0.0275 QALYs worth $1375.
- The authors conclude the tool shows potential savings of up to $2432 per person in total, or $7380 per year assuming 70% compliance, supporting it as a treatment alternative.
Chronic pain
Research from anesthesiology, pain and critical care journals, sourced from PubMed.
Sorted by publication date, not import date. Recent filters exclude papers with only a publication year; find those under All years.
AI-generated abstract summaries can contain errors. Verify findings against the original paper before applying them to patient care.
Last successful paper check: 16 Nov 2026 17:18 UTC.
0 newly discovered papers saved; these are not necessarily published today.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
2 papers awaiting AI summaries. Summary processing had an error; paper-fetch status is separate.
Background checks run while the server is active. This does not guarantee a daily run if hosting sleeps.
- Cross-sectional baseline analysis of 598 patients with lumbar spinal stenosis from two spine clinics, split into low (226) and high (108) recovery expectation groups.
- Network analysis compared associations among symptom duration and PROMIS-29 + 2 domains between the low and high expectation groups.
- The two networks showed no significant structural differences and stable strength centralities, and chronicity had no significant associations with other factors in either network.
- Pain interference and fatigue were the most influential factors in both groups, while anxiety was more influential in the low-expectation group.
- Retrospective MarketScan claims study (2016 to 2023) of 22,955 adults newly prescribed neuropathic pain medication within 60 days of a painful diabetic neuropathy diagnosis.
- Initial agents were gabapentin (59.0%), tramadol (15.1%), oxycodone (7.0%), pregabalin (5.3%) and duloxetine (5.2%), and 98.5% started monotherapy.
- Most gabapentin, pregabalin and duloxetine starters received daily doses below recommended levels (79%, 91% and 61%), and over 50% stopped their first treatment within 3 months.
- About 75% discontinued within 12 months and fewer than 25% switched; by the fourth treatment episode, almost 65% had stopped all pain medications, which the authors attribute to tolerability and inadequate relief.
- Multicenter retrospective cohort of 359 adults with vertebrogenic low back pain and Modic I or II changes who underwent BVNA at seven US centers from 2022 to 2025.
- Patients were grouped by radiofrequency lesion strategy: uniform 7-minute, uniform 15-minute, or mixed 7- and 15-minute lesions.
- Unadjusted ≥50% responder rates were 54.0%, 59.3%, and 73.5% (P = .005); after propensity weighting, mixed versus 15-minute OR was 2.01 (95% CI 0.88–4.59; P = .098).
- The authors found no statistically significant outcome differences across lesion strategies after adjustment, noted that male sex was linked to lower response, and called for prospective studies.
- Systematic review of 13 randomized controlled trials of physical activity-based interventions in surgical patients assessed at three or more months after surgery, pooling 1155 patients across four surgery types.
- Physical activity programs, varying in modality, duration, frequency and session length, were compared with control groups, and only two studies used active controls.
- The authors reported low-quality evidence that physical activity significantly reduced chronic post-surgical pain versus control, with two studies showing reductions exceeding minimal clinically important differences; only three studies were rated low risk of bias.
- The authors concluded the evidence is insufficient to establish definitive efficacy and recommended clearly defined intervention parameters, active controls and more comprehensive pain assessments in future trials.
- Double-blinded randomized phase I/II trial of 58 participants with radicular pain from lumbosacral spinal stenosis.
- Transforaminal injection of sterile amniotic fluid filtrate was compared with dexamethasone, with safety and pain and function outcomes followed to 6 months.
- At 3 months, more dexamethasone patients had at least 50% pain reduction: back 45.8% vs 15.0% (P=.050) and leg 60.0% vs 25.0% (P=.034).
- Adverse event rates were comparable between groups with no serious intervention-related events, and the trial was stopped early after dexamethasone showed greater benefit.
- Observational study of 138 parents of children aged 7 to 12 after tonsillectomy, who completed smartphone diaries three times daily for 7 days.
- Exposure was parents' affect (pain catastrophizing, negative and positive affect), and the outcomes were perceived child pain and home opioid administration.
- In multilevel models, average and momentary parent affect predicted perceived child pain, while average negative affect and momentary affect predicted opioid administration odds.
- Parent pain catastrophizing had a bidirectional lagged relation with perceived child pain, and the authors suggest momentary affect assessment may capture shifts that precede escalations.
- This preclinical study used the uPA mouse model of chronic back pain, examining male and female mice and lumbar dorsal root ganglia against sham controls.
- Behavioral testing, whole-cell patch clamp recordings, flow cytometry, and RNA sequencing were used to compare uPA-CBP mice with sham animals.
- uPA-CBP DRG neurons showed increased excitability, with sex-specific differences in myeloid cells in males and CD4+ T cells in females; no numerical effect sizes are reported in the abstract.
- The authors conclude that sex-specific neuroimmune changes at the DRG may reveal new analgesic targets along the neuroimmune axis.
- Qualitative study of semi-structured interviews with 22 health and medical professionals working with refugees across resettlement settings in ten countries, analysed by reflexive thematic analysis.
- Professionals described refugee pain as intertwined with trauma, loss, and cultural dislocation, and saw loss of autonomy, invalidation, and disrupted social networks as undermining engagement with care.
- Three themes were identified: adversity and pain are intertwined, disempowerment shapes engagement, and barriers within and beyond the health system, including communication, cultural safety, and unmet training needs.
- The authors argue these perspectives should inform the design and delivery of services for refugees with chronic pain and complex needs.
- Retrospective cohort of 44 patients with advanced knee osteoarthritis and chronic knee pain unresponsive to at least 3 months of conservative care.
- Ultrasound-guided radiofrequency ablation of three genicular nerves, with NRS and WOMAC scores assessed at baseline and at 1, 6, and 12 months; no comparator group was reported.
- NRS and WOMAC scores fell significantly at all follow-ups (p<0.001); clinical success (≥50% pain reduction) was 81.8% at 1 month, 75.0% at 6 months, and 11.4% at 12 months.
- Authors conclude benefit was greatest within 6 months, suggesting GNRFA is a medium-term option rather than a permanent one; no serious adverse events were reported.
- In 75 healthy adults aged 21 to 80, researchers used a perceptual decision-making task with warm-versus-cold thermal contrasts to elicit paradoxical heat sensation.
- Hierarchical multivariate Bayesian models compared two a priori profiles: clear "true perceivers" and ambiguous "unsure perceivers", using choices, response times, and confidence ratings.
- At the group level, the unsure perceiver model best explained behaviour, suggesting PHS is usually an uncertain experience rather than a categorical misperception.
- Both profiles appeared across individuals, and older adults reported PHS more often at lower contrasts, but their profiles did not differ from younger participants.
- A qualitative evidence synthesis of 22 studies covering 292 children aged 6-18 and 194 parents, 84% of whom were mothers.
- It examined perceptions of factors shaping therapeutic interactions with health professionals during chronic pain care, synthesised thematically.
- One overarching theme with six sub-themes emerged; of 14 findings, 5 (36%) had moderate, 8 (57%) low, and 1 (7%) very low GRADE-CERQual confidence.
- The authors conclude that past pain care experiences shape future engagement and propose a conceptual framework to help clinicians nurture therapeutic interactions.
AI summary not available. Read the source abstract on PubMed.
- Multicenter randomized controlled trial of 48 patients with lumbar spinal stenosis, reporting outcomes out to five years.
- Interspinous fixation device (IFD) with indirect decompression was compared with standard open direct decompression; five-year data were reported for 18 IFD and 25 decompression patients.
- At five years, the IFD group improved significantly on ODI (-53%), VAS-leg (-66%), VAS-back (-60%) and ZCQ (-29%); decompression improved on three of four measures, not VAS-leg (-64%).
- The authors report comparable overall clinical success and favorable IFD perioperative metrics, including 80% less blood loss, but describe the comparisons as exploratory.
- Benchmark study of three LLMs classifying 318 guideline-derived spine intervention scenarios across 12 procedure categories, including 102 absolute and 57 relative contraindications plus 159 controls.
- Each model was tested at baseline and with retrieval-augmented generation (RAG) using the IPSIS Safety Practices guidelines.
- Accuracy rose from 85.8%-87.1% at baseline to 92.5%-98.4% with RAG (all p < 0.05), and relative-contraindication accuracy rose from 42.1%-56.1% to 59.6%-93.0%.
- Absolute contraindications were identified reliably (safety catch rates 99.0%-100.0%), but relative contraindications were less consistent, and the authors support further evaluation of guideline-augmented LLMs for pre-procedural screening.
- Single-center retrospective review of 410 consecutive medial branch blocks performed in 2019 by four fellowship-trained physiatrists.
- All procedures used anesthetic only, 0.25 or 0.5 mL of 2% lidocaine or 0.5% bupivacaine, with no comparator group.
- Eight patients (1.95%; 95% CI 0.85-3.81%) met criteria for prolonged response, with minimum confirmed relief lasting 21 to 331 days (median 53).
- The authors conclude that routine anesthetic-only blocks do not appear to offer therapeutic benefit, and 11 more patients (2.7%) stopped treatment without documented reason.
- This systematic review pooled eight case-control studies comparing Parkinson's patients with pain, without pain, and healthy controls, totaling 432, 225, and 257 participants.
- The exposure was pain status in Parkinson's disease, examined with structural and resting-state fMRI rather than a treatment intervention.
- Structural MRI showed prefrontal cortical thinning and reduced insular gyrification, and putamen activity was negatively correlated with pain while raphe connectivity was positively associated. The abstract reports no pooled effect sizes, CIs, or p values.
- The authors propose a network-based framework for Parkinson's pain and call for multimodal, longitudinal studies by pain subtype and dopaminergic response. Dynamic default mode and frontoparietal connectivity showed no consistent pain links.
- This narrative review synthesizes epidemiologic and mechanistic evidence on central sensitization, chronic pain, and cognitive vulnerability in midlife, with no pooled sample size reported.
- The authors discuss measurement approaches for sensitization-related physiology, including quantitative sensory testing, neuroimaging, metabolomics, and blood-based vibrational spectroscopy.
- They report biological overlap between sensitization-related physiology and brain-aging processes, but state the evidence does not establish that central sensitization independently accelerates cognitive aging or causes neurodegeneration.
- The authors propose a hypothesis-generating framework treating persistent sensitization physiology as one candidate component of systems-level CNS resilience, requiring prospective longitudinal testing.
- Preclinical study in female C57BL/6J mice using a supradural acid-injection model of dural hypersensitivity, with patch-clamp recordings from dural trigeminal ganglion neurons.
- The peripherally restricted cannabinoid PrNMI (5 µM) was compared with the CB1R agonist ACEA and the CB2R agonist RNB61, each coapplied with the acidic saline.
- PrNMI and ACEA prevented both initial and latent allodynia, while RNB61 did not, and CB1R or CB2R inverse agonists abolished PrNMI's preventive effect.
- The authors conclude that PrNMI prevents acid-induced sensitization by coactivating neuronal CB1Rs and non-neuronal CB2Rs, and that its efficacy was lost once sensitization was established.
- This case series describes two patients with isolated pseudoarticulation between lumbar transverse processes and the iliac crest, which the authors distinguish from Bertolotti's syndrome.
- Both patients received image-guided corticosteroid injection, and the second case used the same injection protocol as the first.
- The first patient had substantial, durable pain relief, while the second had significant but transient relief; the abstract reports no effect sizes or p values.
- The authors suggest this pain source may be under-recognized and that injections could help with localization and prognostication.
- Prospective single-arm pilot trial in consecutive patients with chronic postsurgical pain after total knee arthroplasty; 5 of 15 screened patients completed the study.
- Patients received cooled radiofrequency ablation (Coolief system), with change in NRS pain score from baseline to 6 months as the primary endpoint.
- The NRS change did not reach statistical significance at 6 months, though responder analysis showed a substantial proportion with clinically meaningful improvement; the KSS trend was also nonsignificant.
- No adverse events were reported, and the authors conclude the approach appears safe and potentially effective, with larger studies needed.
- Preclinical study in male rats with tibial-sparing nerve injury, where SCS responders and nonresponders were classified by how much SCS reduced mechanical hypersensitivity.
- Nonresponders received a subtherapeutic dose of the selective A3 adenosine receptor agonist 2-Cl-IB-MECA alone or combined with acute or repeated SCS.
- The low-dose agonist alone produced minimal pain inhibition, but combined with SCS it restored analgesic responses to both acute and repeated stimulation.
- Repeated SCS reduced microglial activation and shifted microglia toward an anti-inflammatory phenotype, suggesting persistent microglial activation may contribute to SCS nonresponsiveness.
- Randomized, sham-controlled, double-blind trial of 94 adults with chronic neuropathic pain, with responders and nonresponders followed in later parts.
- Five days of prolonged continuous theta burst stimulation (pcTBS), 10-Hz rTMS, or sham over left M1; nonresponders then received left DLPFC stimulation.
- Both active M1 groups reduced pain from baseline (10-Hz 37.9 ± 17.5 vs 48.5 ± 16.0, P < .001; pcTBS 35.1 ± 15.3 vs 47.1 ± 15.1, P < .001), with no difference between them (P = .16).
- pcTBS produced faster corticospinal excitability changes than sham (MEP 188.5 ± 39.8 vs 102.2 ± 6.9, P = .044). The authors conclude pcTBS is comparable to 10-Hz rTMS with substantially less treatment time.
- Secondary longitudinal mediation analysis of a 3-arm randomized trial (N = 223) in chronic low back pain, pooling 8-session CBT and 1-session Empowered Relief versus 1-session health education.
- Latent growth curve models tested whether changes in pain intensity, interference, catastrophizing, and self-efficacy over 3 months mediated improvements in sleep.
- Reductions in pain interference and catastrophizing were linked to indirect pathways to better sleep, while pain intensity was not, and self-efficacy showed a partial pathway.
- The authors suggest that targeting pain interference and pain-related cognitions may produce benefits across both sleep and pain; the abstract reports no effect sizes or confidence intervals.
- Case-control MRI study comparing 40 patients with non-specific chronic spinal pain against 60 controls, examining gray and white matter structure.
- Gray matter morphometry from T1-weighted images and white matter diffusion measures from diffusion-weighted imaging were compared between the two groups.
- Patients had significantly reduced gray matter volume in several pain processing and modulation regions, and increased mean and axial diffusivity in a few white matter regions.
- Imaging measures correlated with clinical scores, which the authors interpret as reflecting worse physical and mental health.
- Within-subject fMRI study of 31 participants comparing watch, cognitive reappraisal, and action simulation conditions during vicarious pain.
- Cognitive reappraisal and action simulation were each compared against passive watching during vicarious pain ratings.
- Both strategies reduced vicarious pain ratings, with reappraisal giving stronger regulation but longer response times; the abstract gives no effect sizes or p values.
- Authors propose a dual-pathway model in which action simulation is a less cognitively demanding route, with a sensorimotor link between left dmPFC and postcentral gyrus.
- Registry cohort of 22,771 patients from the Swedish Quality Registry for Pain who underwent interdisciplinary pain rehabilitation between 2016 and 2023.
- Deterioration was assessed with the Reliable Change Index across 18 patient-reported measures at the end of rehabilitation, with no comparator group.
- About 23% of patients had reliable deterioration on at least one measure, most often physical and pain-related measures, and 44.5% had mild deterioration on at least one measure.
- The authors conclude that negative short-term outcomes are common enough to warrant identifying affected patients and investigating the mechanisms behind them.
- Psychometric validation study of 536 children and adolescents aged 8-18 recruited from three hospital units in Spain, with a 50-participant retest subsample at 3 months.
- No intervention was tested; the Spanish 11-item Tampa Scale of Kinesiophobia (TSK-11) was compared against measures of pain intensity, interference, catastrophizing, pain anxiety, and physical functioning.
- Internal consistency was good (α=.88 total), test-retest reliability was excellent (ICC=.89), and confirmatory factor analysis supported the expected two-factor structure.
- Youth with chronic pain (M=24.70) and chronic post-surgical pain (M=27.81) scored higher than those without chronic pain (M=22.89), with correlations of r=.55 to .63 with related constructs.
- Retrospective single-center observational study of 60 patients with pancreatic cancer pain who received fluoroscopy-guided celiac plexus block, split into CPB-only (n = 34) and CPB plus botulinum toxin A (n = 26) groups.
- The comparison was CPB with BTX versus CPB alone, with pain (NRS), opioid use (MME), and rescue interventions tracked at 4, 8, and 12 weeks.
- The 4-week positive responder rate was 65.4% with BTX versus 8.8% without (p < 0.001), and BTX was independently associated with treatment success (OR = 20.75, p < 0.001).
- The authors conclude BTX may be a non-destructive adjunct to CPB, with no serious adverse events reported, and call for prospective validation.
- Secondary analysis of the no-intervention control group of the WalkBack trial, including 301 adults with low back pain who had recovered from an episode, followed for 12 months.
- Fifteen candidate prognostic factors were measured at baseline, and disability was self-reported at 3, 6, 9 and 12 months using the Roland-Morris Disability Questionnaire, summarised as an area under the curve.
- Higher body mass index (β = 0.27, 95% CI 0.04-0.49), worse previous pain intensity (β = 1.10, 95% CI 0.28-1.92), higher perceived recurrence risk (β = 0.71, 95% CI 0.14-1.28) and depressive symptoms (β = 0.61, 95% CI 0.18-1.05) were associated with greater 12-month disability burden.
- Each factor had a small, unique effect, and the authors suggest these findings may inform risk assessment and prevention of future disability after apparent recovery.
- Preclinical study using peripheral nerve injury models to examine PTP1B expression in dorsal root ganglion nociceptors.
- Investigators overexpressed and knocked down PTP1B in nociceptors, and tested Src and GluN2B inhibition on pain-like behavior and synaptic currents.
- Nerve injury sustainedly upregulated PTP1B, mainly in non-peptidergic nociceptors; overexpression produced neuropathic pain-like behaviors and knockdown reversed established hypersensitivity.
- The authors propose PTP1B as an upstream regulator of a presynaptic Src/GluN2B pathway and a potential therapeutic target for neuropathic pain.
- Cross-sectional study of 500 consecutive patients with type 2 diabetes, grouped by standard treatment, SGLT2 inhibitors, or GLP-1 receptor agonists.
- GLP-1 RA treatment was compared with standard care and SGLT2 inhibitors, with DPN assessed by examination, nerve conduction, and skin biopsy when indicated.
- After adjustment, GLP-1 RA use was associated with lower odds of DPN (OR 0.60, 95% CI 0.37-0.96) and painful DPN (OR 0.32, 95% CI 0.15-0.65).
- Unadjusted DPN rates were 46.4% vs 60.6% and painful DPN 10.1% vs 35.1% versus standard care; authors call for longitudinal studies.
- Prospective quasi-randomized controlled trial of 109 patients with persistent pain after knee arthroplasty, assigned by procedure group to genicular nerve treatment.
- Compared conventional radiofrequency thermocoagulation (RFT) with chemical neurolysis using phenol of the genicular nerves.
- Phenol had lower NRS at 1 month (3.67 vs 4.09, p=0.015) and 6 months (5.02 vs 6.52, p<0.001); 6-month ≥50% improvement was 43.6% vs 18.5% (p=0.005).
- Authors conclude both treatments are effective for persistent post-arthroplasty pain, complications were similar (5.5% vs 3.7%), and phenol's short-term benefit needs long-term confirmation.
- Cross-sectional psychometric study of 263 adolescents aged 10-18 with chronic musculoskeletal pain at a tertiary pain center, 84.4% female.
- The 3-item PEG scale was examined for convergent validity against clinical variables and for a cut-off score identifying high-impact chronic pain, defined by upper-tertile functional disability.
- PEG correlated with functional disability (r = 0.63) and quality of life (r = -0.56); ROC analysis gave AUC 0.81, sensitivity 0.75, specificity 0.76, and a PEG cut-off of 6.
- The authors propose the PEG as a brief monitoring and status tool to support risk-stratified care and clinical research in pediatric chronic musculoskeletal pain.
- This PRISMA systematic review pooled 19 studies, including sham-controlled trials, active-comparator trials and cohorts, of genicular nerve block and radiofrequency ablation for knee osteoarthritis.
- Pooled random-effects meta-analysis was used where data were homogeneous, and structured narrative synthesis otherwise.
- RFA was associated with larger and more durable pain relief than GNB, often lasting 6-12 months, though most of the comparison evidence is indirect.
- Both approaches reduced pain with no serious procedure-related adverse events reported, and the authors call for head-to-head trials with standardised protocols and longer follow-up.
- Preclinical mouse study of spared nerve injury neuropathic pain examining parabrachial Npy1r-expressing neurons; about 19% of lateral PBN neurons express Npy1r.
- Y1 receptor activation or chemogenetic inhibition of these neurons reduced injury-induced mechanical and cold allodynia, and ablation before injury delayed hypersensitivity onset.
- Repeated chemogenetic activation in uninjured mice produced mechanical and cold hypersensitivity that persisted after the activation ended.
- The authors conclude these neurons selectively govern the sensory-discriminative component of neuropathic pain, with projections to amygdala, hypothalamus, zona incerta and thalamus.
- The article draws on animal and human studies to examine the hippocampus's role in pain; the abstract does not state the study design or sample.
- No intervention, comparator, or exposure is described; the paper appears to be a broad synthesis of existing work.
- The authors state that current evidence positions the hippocampus as a key contributor to the pain experience, with no effect sizes or statistics reported.
- They aim to offer conceptual insight and novelty for future interdisciplinary pain research.